FDA Releases 14 New Drug Rejection Letters After 3‑Month Pause in Transparency Policy on July 13, 2026 Application procedure CHARGE Syndrome Complete Response Letters concerns CRLs drug rejection letters Effectiveness manufacturing deficiencies Pauses Policy Safety United States Food and Drug Administration +
Voyager Therapeutics Pauses Alzheimer's APOE Program 8 Months After Unveiling on March 11, 2026 Alzheimer 's APOE program Pauses tau therapy Voyager Therapeutics VY1706 VY7523 +
Aardvark Therapeutics Stock Plunges 54% Following Phase 3 Trial Pause on March 02, 2026 AARD gene Aardvark Therapeutics analysts ARD-101 BioNTech cardiac safety clinical development DualityBio Pauses Phase 3 trial Prader-Willi Syndrome therapeutic autologous dendritic cells +
Biopharma Bites: uniQure Pauses AMT-191 Dosing, GSK's Nucala Gets EU Nod, Gilead CAR-T Label Update on February 10, 2026 AMT-191 Approved CAR-T dosing EU Fabry Disease gene therapy Gilead Labels (device) Nucala Pauses SmithKline Beecham uniQure update +
Intellia Pauses Two CRISPR Trials After Severe Liver Toxicity Hospitalizes Patient on October 28, 2025 Clustered Regularly Interspaced Short Palindromic Repeats Gene Modification Hospitalization Intellia Liver Pauses Phase 3 Clinical Trials Safety Senile cardiac amyloidosis Toxicity aspects +
AstraZeneca Pauses £200M Expansion in UK Amid Pharma Uncertainty on September 15, 2025 AstraZeneca Cambridge expansion Investments Pauses Pharma UK +
Eli Lilly Pauses UK Biotech Incubator Plans Amid Concerns Over NHS Drug Pricing on September 12, 2025 Biological Science Disciplines biotech incubator biotech industry Eli Eli Lilly Gateway Labs government Investments Nance-Horan syndrome Pauses pharmaceutical innovation UK +
Elevidys Sales Surge in Sarepta Q2 2025 Despite Safety Concerns on August 07, 2025 Elevidys gene therapy Pauses Performance Safety Issues Sales - occupational activity United States Food and Drug Administration +
FDA Reverses Course, Allows Sarepta to Resume Duchenne Gene Therapy Shipments on July 29, 2025 Elevidys gene therapy Muscular Dystrophy, Duchenne Pauses Resumption Safety shipment United States Food and Drug Administration +
FDA Official Says Sarepta Faces Major Hurdles to Reintroduce DMD Therapy Elevidys on July 25, 2025 approval status CBER concerns Elevidys gene therapy Muscular Dystrophy, Duchenne Pauses Safety Scientific Study shipment United States Food and Drug Administration +
Sarepta, bowing to FDA pressure, pauses shipments of Duchenne gene therapy Elevidys on July 22, 2025 Elevidys gene therapy Muscular Dystrophy, Duchenne patient deaths Pauses Safety shipment United States Food and Drug Administration +
Pharma stocks swerve as Trump hits pause on most tariffs on April 10, 2025 Market Pauses Transplant Registry Unified Management Program +